AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04655131 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation
Study NCT03454542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Modified Lens Design
Description: Randomized in a daily wear, single day (6 hours or more) evaluation
Study NCT01803061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebCan
Description: Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
Study NCT02533284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
Study NCT02533284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupevecaine
Description: US guided TAP using Bupevecaine 0.25 %
Study NCT02533284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: US guided TAP using placebo (saline)
Study NCT02087735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cranberry extract
Description: The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
Study NCT02087735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cranberry extract
Description: The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
Study NCT01481597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deuteporfin
Description: deuteporfin 1 mg/kg IV as a single dose
Study NCT01481597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 2.5 mg/kg IV as a single dose
Study NCT01481597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 5 mg/kg IV as a single dose
Study NCT01494441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP
Description: The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
Study NCT01494441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rhBMP-2/BCP/TSRH® Spinal System
Description: rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
Study NCT01481597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: deuteporfin
Description: deuteporfin 7.5 mg/kg IV as a single dose
Study NCT01494441 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft/TSRH® Spinal System
Description: The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
Study NCT01481597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
Study NCT01551992 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quill suture vs. Interrupted suture
Description: To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
Study NCT03737942 — intervention group
Intervention type: DEVICE
Intervention: monitoring of neuromuscular function
Description: started by percutaneous stimulation of the cubital nerve at the wrist level
Study NCT03031197 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tailored realtime triggered reminder pkg
Description: Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence.
Study NCT04493073 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectulectomy
Description: decrease IOP
Study NCT04493073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Decrease bleb failure
Study NCT04290117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Training
Description: During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
Study NCT04290117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training
Description: During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.
Study NCT04290117 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and bright light in the morning
Description: During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
Study NCT04290117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene and bright light in the morning
Description: During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
Study NCT03582410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with absorbable suture
Description: laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture
Study NCT03582410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with non absorbable suture
Description: laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
Study NCT00971022 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: 20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
Study NCT00971022 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: 5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
Study NCT04074577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique First
Description: colonoscopy without automated polyp detection software
Study NCT04074577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: combination technique First
Description: automated polyp detection software
Study NCT02705937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy product
Description: Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
Study NCT02705937 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aequasyal mouth spray
Description: The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
Study NCT03046628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green laser (at 532nm) and a fast camera
Study NCT02705183 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Multifractionated post-operative radiotherapy, several weeks after surgery
Study NCT03624166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia
Study NCT03624166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: patients will receive 3 ml of isotonic saline after spinal anesthesia
Study NCT04488783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc and ascorbate
Description: oral zinc and ascorbate
Study NCT01852526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: hybrid system
Description: The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
Study NCT01100996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control enteral nutrition
Description: This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
Study NCT01100996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enriched enteral feeding
Description: This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
Study NCT01774344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib, 40 mg tablets
Study NCT01774344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance
Study NCT01852526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: hybrid system
Description: The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
Study NCT01852526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Plif
Description: monosegmental PLIF
Study NCT01852526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: Plif
Description: monosegmental PLIF
Study NCT01763281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRH
Study NCT01763281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01374776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous iron carboxymaltose
Description: The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
Study NCT03555084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extension of Virto B-Titanium
Description: In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
Study NCT03555084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virto B-Titanium
Description: In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
Study NCT00941954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Education
Description: The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.
Study NCT00941954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
Study NCT01185145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast Brachytherapy with Mammosite RTS
Description: Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
Study NCT00361283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
Study NCT01185145 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
Study NCT03365427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
Study NCT00997386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan, and melphalan, and alemtuzumab
Description: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.
Study NCT04077632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
Study NCT04077632 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
Study NCT03958734 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal
Description: Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
Study NCT02781766 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Thrombin generation measurement.
Study NCT04116203 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Manufacturer's standard 500 mg. Submission Control No.:128147
Study NCT04116203 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Fish Oil and Metformin
Description: Combo of 2 other arms
Study NCT04116203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish Oil
Description: NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
Study NCT01872026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study NCT02792374 — intervention group
Intervention type: OTHER
Intervention: Psychological Measurement
Description: Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
Study NCT01830946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
Study NCT01830946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Combined Resistance and High-Intensity Interval training
Description: Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
Study NCT01830946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Resistance and High-Intensity Interval training
Description: Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
Study NCT01830946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein Protein
Description: Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
Study NCT00777816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
Study NCT00777816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
Study NCT02747602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
Study NCT00624858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone SR 32 mg/ bupropion SR 360 mg daily
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise
Study NCT03499756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based interpersonal psychotherapy
Description: The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
Study NCT02194413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: receiving healing touch